LIBTAYO is a medicine approved by the Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.
Immunotherapy can help the body’s immune system fight cancer. LIBTAYO is a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.
LIBTAYO may be right for people with advanced CSCC that:
has spread (metastasized)OR
cured by surgery or radiation
Ask your healthcare provider whether LIBTAYO is a treatment option you should consider.
Actual patient. Individual results may vary.
Chris shares her story about living with metastatic CSCC. Listen as she takes you through her journey, from initially being misdiagnosed to the chaIlenges she faces managing life with metastatic CSCC, and her treatment experience with LIBTAYO.